Inspira™ Introduces Advanced Features for INSPIRA™ ART100, Further Amplifying User and System Support

Rhea-AI Summary

Inspira Technologies (Nasdaq: IINN) has announced new support features for its FDA-cleared INSPIRA™ ART100 system, enhancing medical team procedures and efficiency in extracorporeal life support technology. The updates include integration with hospital procedures, system-activated alarm troubleshooting, and advanced software display features for complex care situations.

The ART100 system adds oxygen to blood and removes carbon dioxide, functioning as a heart-lung support for critical care patients. Key features include a compact design, four-hour emergency uptime, and compatibility with various disposable equipment. The system received FDA 510(k) clearance for CBP procedures and Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures in May and July 2024.

Positive

• FDA 510(k) clearance obtained for INSPIRA ART100
• Israeli AMAR certification received for multiple procedures
• System provides 4-hour emergency uptime capability
• Compatible with various market-available disposable equipment

Negative

• Other key products still in development phase without regulatory approval
• Operating in highly competitive $19B mechanical ventilation market

Insights

Medical Technology Analyst

The introduction of advanced features for the INSPIRA ART100 system represents a strategic move in Inspira's product evolution, particularly following its recent FDA 510(k) clearance and Israeli AMAR certification. The enhancements address three critical areas in acute care settings:

• Integration with hospital procedures and safety practices, reducing implementation barriers
• Advanced alarm troubleshooting systems, important for high-stress scenarios
• Improved visual information display for isolated or in-transit patient care

These updates align with the broader industry trend toward more intuitive medical devices, as healthcare facilities face persistent staffing challenges and increasing patient loads. The timing is particularly relevant given the recent regulatory approvals, as it demonstrates continued product development momentum and responsiveness to user feedback.

The market implications are nuanced. While these features may not directly drive significant new sales, they could accelerate adoption rates among existing customers and reduce training overhead, particularly important for a novel technology entering the established $19 billion mechanical ventilation market. The focus on user experience and workflow integration suggests a mature product development strategy, moving beyond core functionality to address practical implementation challenges.

The development of the HYLA blood sensor and real-time monitoring capabilities positions INSPIRA ART100 as a comprehensive platform rather than just a device, potentially creating stronger competitive barriers and higher switching costs for customers. This platform approach, combined with the recent regulatory approvals and feature enhancements, could strengthen Inspira's position in negotiations with potential distribution partners and healthcare systems.

RA'ANANA, Israel, Jan. 27, 2025 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira," or the "Company"), a leader in innovative medical technology, has announced the addition of new support features to the INSPIRA™ ART100, a system cleared by the U.S. Food and Drug Administration. These enhancements are designed to assist medical team procedures to reduce staff overhead and improve efficiency, further solidifying Inspira's position at the forefront of extracorporeal life support technology.

The new features provide valuable resources for clinical teams using the system within its intent of use. For example, the system is designed to integrate a given hospital's established procedures and safety practices and includes system-activated alarm troubleshooting uniquely designed to provide valuable direction when time is of the essence and user anxiety is running high. The system also provides a prominent screen with advanced software that displays information in an accessible and visible manner during complicated and challenging care situations – for example when the patient is isolated or in-transit.

These new features are intended to further support staff using the INSPIRA ART100's existing advanced and cutting-edge software already designed to navigate the staff through a step-by-step setup process, demonstrating another example of Inspira's dedication through innovation to assist medical teams to manage complex medical procedures more effectively.

"Our goal is to develop systems that support medical professionals in their work to treat patients and save lives", said Dagi Ben-Noon, Chief Executive Officer of Inspira. "These additions reflect our commitment to being pioneers in the life support sector."

The INSPIRA ART100 system utilizes a technique that adds oxygen to the blood and removes carbon dioxide, with the enriched blood being circulated back to the patient, taking over the functionality of the heart and/or lungs in critical care patients. The INSPIRA ART100 has a small footprint design, provides up to four hours of uptime in emergency scenarios, and can be used with various types of disposable equipment available on the market.

Inspira™ Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical technology company targeting to better the life support and respiratory treatment arena. The Company is developing a breakthrough Augmented Respiration Technology (INSPIRA™ ART), a groundbreaking device poised to revolutionize and potentially replace the $19 billion mechanical ventilation market. With 20 million intensive care unit patients with acute respiratory failure each year, many of whom rely on mechanical ventilators, the INSPIRA ART offers a potential alternative by elevating and stabilizing decreasing oxygen saturation levels in minutes without a ventilator, with patients being awake during treatment. The INSPIRA ART is being designed to include the clip-on HYLA™ blood sensor, a real-time continuous blood monitoring technology, aiming to alert physicians of changes in a patient's condition without the need for intermittent actual blood samples, aiming to support physicians in making informed decisions.

In May and July 2024, respectively, the Company's INSPIRA™ ART100 system has obtained FDA 510(k) clearance for use in CBP procedures, along with the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.

The Company's other products and technologies, including the INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device, VORTX™ Oxygen Delivery System, and HYLA™ blood sensor, are currently being designed and developed, and have not yet been tested or used in humans nor approved by any regulatory entity.

For more information, please visit our corporate website at https://inspira-technologies.com

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the intended function and utility of the new support features, its goal to further develop systems that support medical professionals in their work to treat patients and save lives, and its commitment to being pioneers in the life support sector. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.

Contact: Inspira Technologies – Media Relations
Email: info@inspirao2.com 
Phone: +972-9-9664485

Copyright © 2018-2025 Inspira Technologies OXY B.H.N. LTD., All rights reserved.

Logo - https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/inspira-introduces-advanced-features-for-inspira-art100-further-amplifying-user-and-system-support-302360736.html

SOURCE Inspira Technologies

FAQ

What new features were added to the INSPIRA ART100 system in January 2025?

The new features include hospital procedure integration, system-activated alarm troubleshooting, and advanced software display features for complex care situations and patient isolation scenarios.

What regulatory approvals has IINN's INSPIRA ART100 received in 2024?

The INSPIRA ART100 received FDA 510(k) clearance for CBP procedures in May 2024 and Israeli AMAR certification for Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures in July 2024.

What is the emergency uptime duration of INSPIRA ART100?

The INSPIRA ART100 system provides up to four hours of uptime in emergency scenarios.

How does the INSPIRA ART100 system function for patient treatment?

The system adds oxygen to the blood and removes carbon dioxide, with the enriched blood being circulated back to the patient, taking over the functionality of the heart and/or lungs in critical care patients.